



WNICER

WORLDWIDE NETWORK FOR INNOVATION
IN CLINICAL EDUCATION AND RESEARCH

WNICER OVERVIEW

- The Worldwide Network for Innovation in Clinical Education and Research (WNICER) is a multinational not-for-profit network that impacts global health through cutting edge clinical research, timely and pragmatic symposia and continuing medical education (CME) programming, clinical trial design and execution services, artificial intelligence (AI) analytics and decision support tools, and clinically relevant consulting.
- WNICER implements programs that shorten the time from discovery to patient benefit, including:
 - Innovative clinical trials
 - Translational research
 - Implementation strategies that impact clinical care and clinical practice
- WNICER develops insights that increase our knowledge of health and disease leading to:
 - Improved quality of healthcare globally
 - Development of solutions that can improve clinical and economic outcomes
 - Direct benefit to patients, providers, payers, and society
- WNICER maintains dynamic CME capabilities that ensure that clinical trial insights are rapidly disseminated and implemented by healthcare professionals

WNICER NETWORK IN NUMBERS

The Network spans:

- ❖ 10 Countries*
- ❖ 27 Cities
- ❖ 60+ Lead Investigators
- ❖ 400+ Team Members
- ❖ 1 Billion+ Population Base

* USA, Canada, Australia, Brazil, Egypt,
Germany, India, Israel, Mexico, and the UK



CAPABILITIES OVERVIEW

- Consulting
- Clinical Trial Design and Implementation
- Global Clinical Trial Network
- Artificial Intelligence/Machine Learning Data Analytics Platform
- Clinical and Economic Outcomes Studies
- Continuing Medical Education Programs
- Symposia and Conferences
- COVID-19 Clinical Trials
- Sponsor of the Cura Foundation and the Vatican's Pontifical Council for Culture's *Fifth International Vatican Conference*
- Thought Leadership and Key Opinion Leader insights

CONSULTING OVERVIEW

- Content expertise and thought leadership in cardiovascular and cardiometabolic syndromes and related linkages, including:
 - Coronary disease, structural heart disease, heart failure, electrophysiology, cardiac imaging
 - Diabetes mellitus
 - Inflammatory diseases
 - Cardio-oncology
 - Migraine
 - Environmental associations to health and disease
 - Social determinants of disease
- Bench to bedside translation:
 - Pharmacologics
 - Medical devices, wearables, sensors
 - Novel diagnostic and therapeutic pathways
 - Personalized medicine platforms

CONSULTING OVERVIEW (continued)

- Healthcare delivery
 - Integrated systems of care
 - Multidisciplinary clinical program development
 - Cardio-oncology, cardio-diabetes, cardio-neurology, structural heart disease and heart teams, multimodal cardiac imaging
 - Project management/co-management
 - Post COVID-19 telemedicine, virtual care, and remote patient monitoring

CLINICAL RESEARCH PROGRAMS

- Clinical trials consulting: feasibility, design, sample sizing, budgets
- Prospective trial design and execution
- Registry data analysis and research
 - Population health
 - Health outcomes
 - Health economics/outcomes
 - Electronic health records
 - Big data
 - AI
- Project management
- Global sites
- Partnerships with existing academic and clinical research organizations

CLINICAL TRIAL HIGHLIGHTS

Recent and Ongoing Clinical Trials:

- Point-of-care pharmacogenomic testing for personalized antiplatelet therapy after PCI
 - TAILOR PCI (Tailored Antiplatelet Therapy Following PCI) - multi-site, prospective, randomized trial testing the hypothesis that after PCI, using a genotyping strategy is superior to usual care in reducing a composite endpoint of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis (primary endpoints) in CYP2C19 reduced function allele patients. The study enrolled 5,300 patients and was reported as a Late Breaking Clinical Trial at the American College of Cardiology (ACC) Scientific Sessions in March 2020. (<https://clinicaltrials.gov/ct2/show/NCT01742117>).
- COVID-19 Trials
 - TAILOR-COVID: genetic predictors of disease susceptibility and outcome
 - ACT: randomized trial testing utility of hydroxchloroquine, azithromycin, and interferon in a 2x2 factorial design
 - ATTACC: prophylactic versus therapeutic anticoagulation

EDUCATIONAL PROGRAMMING

- Create and manage scientific colloquia in collaboration with clients, focused on important scientific questions tailored to target audiences
- Develop collaborative research symposia
- Produce web-based educational content
- Publish high level manuscripts in high impact journals
- CME development
 - Set objectives
 - Develop high value, state-of-the art content
 - Recruit faculty
 - Apply for accreditation
 - Event management and logistics
 - Communication and marketing
 - Financial management
 - Stakeholder relations
 - Program evaluation



John Brooks III, M.S.
President & CEO



Michael Farkouh, MD
Founder



Vergheese Mathew, MD
Director



Farouk Mookadam, MD
Senior Advisor & Consultant



Kamlesh Thakker, PhD, MBA
Board Member

WNICER Leadership Team



John L. Brooks III, M.S., President and Chief Executive Officer

Mr. Brooks is the Managing Director of Healthcare Capital LLC, which advises earlystage life sciences companies. Healthcare Capital specializes in advancing disruptive and innovative solutions in healthcare, especially in obesity, pre-diabetes, and diabetes. He is on the board of a number of for-profit and not-for-profit organizations.

Mr. Brooks is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.

Mr. Brooks is a well-known life sciences executive. He has co-founded seven life sciences companies. He was a co-founder of Prism Venture Partners, a \$1.25B venture capital firm. Prior to that, Mr. Brooks was a senior medical device executive at Pfizer, and a senior manager at Arthur Andersen & Co. in Boston, MA, where he focused on early stage companies.

A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant.



Michael Farkouh, MD, WNICER Founder

Dr. Farkouh is professor and Vice-Chair, Research, Department of Medicine, at the University of Toronto, and the Peter Munk Chair in Multinational Clinical Trials at the Peter Munk Cardiac Centre, and director of the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research. He is an honours graduate of the Schulich School of Medicine at Western University in London, Canada. Dr. Farkouh completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of Medicine at Mount Sinai New York, respectively, and holds an MSc in clinical epidemiology from McMaster University.

Dr. Farkouh previously served as the founding director of the Mount Sinai CV Clinical Trials Unit in New York City. He has published over 200 papers largely on acute coronary syndromes and cardiovascular prevention. He has published over 200 papers largely on acute coronary syndromes and cardiovascular prevention. He is internationally known for his work on the management of acute coronary syndromes in the emergency room. He directs numerous clinical trials on questions related to diabetes and heart disease including the NIH-sponsored FREEDOM and TAILOR-PCI trials. He received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the Year at the Mayo Clinic, and was awarded the Jan J. Kellermann Memorial Award from the International Academy of Cardiology in 2015.



Verghese Mathew, MD, Director

Dr. Mathew has been a high volume academic interventional cardiologist for more than 2 decades. He was a consultant cardiologist at Mayo Clinic from 1997-2016 where he held numerous leadership positions, with joint appointments in the Departments of Medicine, Cardiology, and Radiology. He was recruited to Loyola University Medical Center in 2016 to be the Director of the Division of Cardiology, where he also held the rank of Professor of Medicine and the William B. Knapp, MD Chair in Cardiology at Loyola University Chicago Stritch School of Medicine.


Dr. Mathew has extensive clinical experience in the field of interventional cardiology, with basic and translational research programs in coronary physiology, complex coronary disease management and outcomes, peripheral arterial interventions, and transcatheter aortic valve replacement (TAVR). He has published extensively, and continues to be an invited speaker at many national and international scientific conferences. He has been a key investigator in many clinical trials that have evaluated and led to the approval of widely utilized medical devices/technologies, such as coronary stents/drug eluting stents and TAVR; pharmacologic studies focused on antiplatelet and anticoagulant drugs in the context of coronary interventions; and personalized, pharmacogenomic-guided approaches to care. Dr. Mathew has deep expertise in integrated models of care, patient-centered process management, and cross-disciplinary clinical program development. Dr. Mathew is board certified in interventional cardiology and cardiovascular diseases, and is a Fellow of the American College of Cardiology and a Fellow of the Society for Cardiovascular Angiography and Interventions.



Farouk Mookadam, MD, Senior Advisor and Consultant

Dr. Mookadam is a non-invasive clinical cardiologist. He completed undergraduate studies at York University Toronto in Biochemistry and Molecular genetics. Completed his medical degree in Johannesburg South Africa and then Internal Medicine and Cardiovascular Disease at McMaster University, Hamilton, Canada. He has a Masters degree in Health Research Methodology with bench and clinical research experience. Dr. Mookadam is Professor Emeritus of Medicine Mayo Clinic College of Medicine having worked for 2 decades as a Consultant in Cardiovascular Diseases. He served in several leadership positions including Medical Director of the Anticoagulation Clinic, Founder and Medical Director of Cardio-Oncology and Service Line and as Associate Chair of research in the Dept. of Medicine and Associate Programme Director for the Internal medicine Residency.

Dr. Mookadam's interests include Clinical Programme and Service Line Development, CME, and a strong career track in research. He has over 220 PubMed indexed peer reviewed publications and several book chapters. He has a proven career in scholarly activity and clinical research as well as Clinical Trial Design. His interests include the metabolic syndrome, cancer and the heart and shared risk factors between cardiovascular disease and cancer. He serves as Adjunct Professor at Arizona State University and collaborates on cardiovascular Physiology and exercise as a cardioprotectant against chemotherapy induced cardiac injury. He has presented at national and international scientific meetings and has served as mentor to young physicians over the years.



Kamlesh M. Thakker, PhD, MBA, Board Member

Dr. Thakker is the Founder/Principal of Notting Hill Consulting LLC, which provides consulting services for pharmaceutical, biotechnology and financial services companies in the areas of Clinical Development and Medical Affairs, Phase I-IV Clinical Pharmacology, PK-PD, and Bioequivalence/Biopharmaceutics. At Abbvie/Abbott, Dr. Thakker individually led/managed teams responsible for Medical Affairs strategy and tactics from clinical development to launch/on-market, across several indications/products/development candidates in the Dyslipidemia, Renal, and Immunology Therapeutic Areas (TAs).

Dr. Thakker also has on-market, pre-launch and launch experience in Cardiovascular Medical Affairs and Clinical Development from his 4+ years at Pfizer with the Hypertension and Lipids on-market franchise products, specifically Norvasc and Caduet. While at Pfizer, he also worked in a Medical Affairs role for development candidates across many different TAs within the New Product Development Group. His Phase I-IV Clinical Pharmacology/Early Development/PK-PD/Biopharmaceutics experience was accumulated while at Pfizer, Ciba-Geigy (now Novartis) and at softgel manufacturer Banner Gelatin Products. Dr. Thakker's Clinical Pharmacology accomplishments while at these companies include several successful prosecutions of NDAs and sNDAs for products across different TAs, and FIH studies for many CNS pipeline development candidates at Pfizer. He has presented and published extensively during his career and has received numerous citations and awards while working with Abbvie/Abbott, Pfizer, Ciba-Geigy and Banner Gelatin.

A stethoscope is positioned diagonally across the left side of the image, set against a background of a light blue ECG (heart rate) line. The stethoscope's chest piece is at the bottom left, and its earpieces curve towards the top left. The ECG line consists of several distinct waveforms.

WNICER

WORLDWIDE NETWORK FOR INNOVATION
IN CLINICAL EDUCATION AND RESEARCH



1-212-618-6325



info@wnicer.org



www.wnicer.org



One Rockefeller Plaza
11th Floor
New York, NY 10020, USA